collection
https://read.qxmd.com/read/31144061/the-next-era-of-renal-radionuclide-imaging-novel-pet-radiotracers
#1
JOURNAL ARTICLE
Rudolf A Werner, Xinyu Chen, Constantin Lapa, Kazuhiro Koshino, Steven P Rowe, Martin G Pomper, Mehrbod S Javadi, Takahiro Higuchi
Although single-photon-emitting radiotracers have long been the standard for renal functional molecular imaging, recent years have seen the development of positron emission tomography (PET) agents for this application. We provide an overview of renal radionuclide PET radiotracers, in particular focusing on novel 18 F-labelled and 68 Ga-labelled agents. Several reported PET imaging probes allow assessment of glomerular filtration rate, such as [68 Ga]ethylenediaminetetraacetic acid ([68 Ga]EDTA), [68 Ga]IRDye800-tilmanocept and 2-deoxy-2-[18 F]fluorosorbitol ([18 F]FDS))...
August 2019: European Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/30252103/new-classification-of-hydronephrosis-on-18f-fdg-pet-ct-predicts-post-operative-renal-function-and-muscle-invasive-disease-in-patients-with-upper-urinary-tract-urothelial-carcinoma
#2
JOURNAL ARTICLE
Seiji Asai, Tetsuya Fukumoto, Ryuta Watanabe, Kanae Koyama, Yuichiro Sawada, Terutaka Noda, Noriyoshi Miura, Yutaka Yanagihara, Yuki Miyauchi, Masao Miyagawa, Tadahiko Kikugawa, Takashi Saika
Objectives: To evaluate the value of a classification of hydronephrosis on 18F-flurodeoxyglucose (FDG)-PET/CT in predicting post-operative renal function and pathological outcomes among patients with upper urinary tract urothelial carcinoma. Methods: We retrospectively reviewed 71 patients treated with nephroureterectomy (NU) for upper urinary tract urothelial carcinoma after FDG-PET/CT between 2010 and 2016. Eight patients treated with ureteral stent or nephrostomy at the time of FDG-PET/CT were excluded...
November 1, 2018: Japanese Journal of Clinical Oncology
https://read.qxmd.com/read/30954190/holmium-166-microsphere-radioembolization-of-hepatic-malignancies
#3
REVIEW
Margot T M Reinders, Maarten L J Smits, Caren van Roekel, Arthur J A T Braat
Holmium microspheres have recently become available in the European market as the third type of microspheres for radioembolization of unresectable liver malignancies. Holmium microspheres come with a dedicated administration system, and since these microspheres contain holmium-166 (166 Ho) instead of yttrium-90, unique dosing and imaging possibilities have become available as well. In addition, a scout dose of 166 Ho microspheres (Conformité Européenne mark is now granted and not pending anymore) can be used instead of 99m Tc-macroaggragated albumin during the preparatory angiography procedure...
May 2019: Seminars in Nuclear Medicine
https://read.qxmd.com/read/31119317/fapi-pet-ct-improves-staging-in-a-lung-cancer-patient-with-cerebral-metastasis
#4
JOURNAL ARTICLE
Frederik L Giesel, Claus Peter Heussel, Thomas Lindner, Manuel Röhrich, Hendrik Rathke, Hans-Ulrich Kauczor, Jürgen Debus, Uwe Haberkorn, Clemens Kratochwil
No abstract text is available yet for this article.
July 2019: European Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/30954939/-68-ga-fapi-pet-ct-tracer-uptake-in-28-different-kinds-of-cancer
#5
JOURNAL ARTICLE
Clemens Kratochwil, Paul Flechsig, Thomas Lindner, Labidi Abderrahim, Annette Altmann, Walter Mier, Sebastian Adeberg, Hendrik Rathke, Manuel Röhrich, Hauke Winter, Peter K Plinkert, Frederik Marme, Matthias Lang, Hans-Ulrich Kauczor, Dirk Jäger, Jürgen Debus, Uwe Haberkorn, Frederik L Giesel
The recent development of quinoline-based PET tracers that act as fibroblast-activation-protein inhibitors (FAPIs) demonstrated promising preclinical and clinical results. FAP is overexpressed by cancer-associated fibroblasts of several tumor entities. Here, we quantify the tumor uptake on 68 Ga-FAPI PET/CT of various primary and metastatic tumors to identify the most promising indications for future application. Methods: 68 Ga-FAPI PET/CT scans were requested by various referring physicians according to individual clinical indications that were considered insufficiently covered by 18 F-FDG PET/CT or other imaging modalities...
June 2019: Journal of Nuclear Medicine
https://read.qxmd.com/read/31099673/the-evolving-role-of-prostate-specific-membrane-antigen-based-diagnostics-and-therapeutics-in-prostate-cancer
#6
REVIEW
Tanya B Dorff, Stefano Fanti, Andrea Farolfi, Robert E Reiter, Taylor Y Sadun, Oliver Sartor
Prostate-specific membrane antigen (PSMA)-based imaging seeks to fill some critical gaps in prostate cancer staging and response assessment, and may select patients for treatment with radiolabeled PSMA conjugates. In biochemical recurrence, at prostate-specific antigen (PSA) levels as low as 0.2 ng/dL, 68 Ga-PSMA imaging has demonstrated a 42% detection rate of occult metastatic disease, and detection has been greater than 95% when PSA levels are higher than 2 ng/dL. This may facilitate novel approaches, including salvage lymphadenectomy or metastasis-directed radiation therapy, in patients with oligometastatic disease...
January 2019: American Society of Clinical Oncology Educational Book
https://read.qxmd.com/read/30911265/immunological-agents-used-in-cancer-treatment
#7
REVIEW
Melih Simsek, Salim Basol Tekin, Mehmet Bilici
Immune checkpoint inhibitors (ICI) are monoclonal antibodies targeting cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), or PD-1 ligand (PD-L1). ICI are approved for the treatment of malign melanoma, non-small cell lung cancer, classical Hodgkin lymphoma, head and neck squamous cell carcinoma, urothelial carcinoma, and renal cell carcinoma. They can lead to long-term anti-tumor responses by deactivating the brake mechanism in the immune system. Ipilimumab, tremelimumab, pembrolizumab, nivolumab, atezolizumab, durvalumab, and avelumab are examples of ICI...
February 2019: Eurasian Journal of Medicine
https://read.qxmd.com/read/30954187/dosimetry-of-y-90-microspheres-utilizing-tc-99m-spect-and-y-90-pet
#8
REVIEW
Bashir A Tafti, Siddharth A Padia
Dosimetry for yttrium-90 radioembolization continues to generate interest and controversy, as multiple approaches have been used effectively. Traditionally, simple formulas primarily based on patients' body weight or perfused liver volume were used. Over the past several years, dosimetry refinements have led to marked improvements in this therapy from both a safety and efficacy standpoint. Technetium-99m macroaggregated albumin single photon emission computed tomography (SPECT) optimizes pretreatment dosimetry to ensure delivery of a therapeutic radiation dose to the tumor while minimizing nontarget radiation to healthy hepatic tissue...
May 2019: Seminars in Nuclear Medicine
https://read.qxmd.com/read/30985421/ensureplus-as-an-alternative-to-the-standardized-egg-gastric-emptying-meal
#9
JOURNAL ARTICLE
Lilja B Solnes, Sara Sheikhbahaei, Harvey A Ziessman
OBJECTIVES: The purpose of this study was to establish normal gastric-emptying values for EnsurePlus in healthy subjects and to determine whether it is an acceptable alternative to the recommended standardized Tc-sulfur colloid egg meal. METHODS: Twenty-one healthy subjects underwent gastric-emptying scintigraphy with In-DTPA EnsurePlus. Normal gastric emptying values were established for 1, 2, 3, and 4 hours after meal ingestion. The gastric-emptying results were compared with another group of normal subjects (n = 18) who ingested the standardized egg meal...
June 2019: Clinical Nuclear Medicine
https://read.qxmd.com/read/31102000/role-of-18f-flt-pet-ct-in-suspected-recurrent-or-residual-lymphoma-final-results-of-a-pilot-prospective-trial
#10
JOURNAL ARTICLE
Lucia Zanoni, Alessandro Broccoli, Alessandro Lambertini, Cinzia Pellegrini, Vittorio Stefoni, Filippo Lodi, Cristina Fonti, Cristina Nanni, Pier Luigi Zinzani, Stefano Fanti
PURPOSE: To evaluate the role of F-18-Fluorothymidine (FLT) PET/CT in lymphoma patients with suspected recurrent or residual disease. METHODS: Adult lymphoma patients presenting with positive or equivocal F-18-FDG PET/CT at end-treatment or follow-up were prospectively addressed to an additional F-18-FLT-PET/CT. SUV max and tumour-to-background ratios (TBRs) were recorded for the most avid lesion. Biopsy or, when not available, clinical or imaging assessment were employed as standard of reference...
May 17, 2019: European Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/31147927/improved-identification-of-patients-with-oligometastatic-clear-cell-renal-cell-carcinoma-with-psma-targeted-18-f-dcfpyl-pet-ct
#11
JOURNAL ARTICLE
Alexa R Meyer, Michael A Carducci, Samuel R Denmeade, Mark C Markowski, Martin G Pomper, Philip M Pierorazio, Mohamad E Allaf, Steven P Rowe, Michael A Gorin
OBJECTIVE: Complete surgical resection of metastatic sites has been shown to prolong survival in select patients with oligometastatic RCC. This treatment strategy is dependent upon the accurate characterization of a patient's extent of disease. The objective of this study was to explore the utility of PSMA-targeted 18 F-DCFPyL PET/CT in patients with presumed oligometastatic clear cell RCC. METHODS: This is a subset analysis of a prospective study in which patients with RCC were imaged with 18 F-DCFPyL PET/CT (ClinicalTrials...
August 2019: Annals of Nuclear Medicine
https://read.qxmd.com/read/30374849/the-need-for-standardization-of-nuclear-cardiology-reporting-and-data-system-ncad-rads-learning-from-coronary-artery-disease-cad-breast-imaging-bi-liver-imaging-li-and-prostate-imaging-pi-rads
#12
EDITORIAL
Majid Assadi, Erik Velez, Mohammad Hosein Najafi, Ali Gholamrezanezhad
Newer structured reporting manners, the reporting and data system (RADS), have made vast steps in improving standardized and structured reporting, allowing better communication between radiologists and referring providers. This has been implemented in several fields: breast (BI-RADS), lung (Lung-RADS), liver (LI-RADS), thyroid (TI-RADS), prostate (PI-RADS), and in cardiovascular radiology (CAD-RADS). The field of nuclear cardiology began its efforts of standardization years ago; however, a widespread standardized reporting structure has not yet been adopted...
April 2019: Journal of Nuclear Cardiology
https://read.qxmd.com/read/31092382/neuroendocrine-differentiation-in-castration-resistant-prostate-cancer-nuclear-medicine-radiopharmaceuticals-and-imaging-techniques-a-narrative-review
#13
REVIEW
Sharjeel Usmani, Marina Orevi, Antonella Stefanelli, Alberto Zaniboni, Ofer Nathan Gofrit, Claudio Bnà, Sonia Illuminati, Giulia Lojacono, Silvia Noventa, Giordano Savelli
BACKGROUND: Androgen Deprivation Therapy (ADT) is the primary treatment for patients suffering from relapsing or advanced prostate cancer (PC). Hormone therapy generally guarantees adequate clinical control of the disease for some years, even in those patients affected by widespread skeletal and soft tissue metastases. Despite ADT, however, most patients treated with hormones eventually progress to castration-resistant prostate cancer (CRPC), for which there are no effective treatments...
June 2019: Critical Reviews in Oncology/hematology
https://read.qxmd.com/read/31100231/heterogeneous-flare-in-prostate-specific-membrane-antigen-positron-emission-tomography-tracer-uptake-with-initiation-of-androgen-pathway-blockade-in-metastatic-prostate-cancer
#14
JOURNAL ARTICLE
Rahul Aggarwal, Xiao Wei, Won Kim, Eric J Small, Charles J Ryan, Peter Carroll, Matthew Cooperberg, Michael J Evans, Thomas Hope
BACKGROUND: Prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET) imaging is a highly sensitive tool for the detection of prostate cancer metastases. However, the effect of primary and secondary androgen deprivation therapy (ADT) on PSMA PET uptake has not been described. OBJECTIVE: To prospectively evaluate changes in 68 Ga-PSMA-11 PET uptake on initiation of androgen receptor (AR)-targeted therapy. DESIGN, SETTING, AND PARTICIPANTS: Prospective single-institution study of patients with metastatic castration-sensitive (n=4) and castration-resistant prostate cancer (n=4) starting treatment with ADT and enzalutamide, respectively, who underwent serial 68 Ga-PSMA-11 PET imaging before and after treatment initiation...
May 2018: European Urology Oncology
https://read.qxmd.com/read/29725716/-68-ga-psma-11-pet-ct-derived-metabolic-parameters-for-determination-of-whole-body-tumor-burden-and-treatment-response-in-prostate-cancer
#15
JOURNAL ARTICLE
Christian Schmidkonz, Michael Cordes, Daniela Schmidt, Tobias Bäuerle, Theresa Ida Goetz, Michael Beck, Olaf Prante, Alexander Cavallaro, Michael Uder, Bernd Wullich, Peter Goebell, Torsten Kuwert, Philipp Ritt
PURPOSE: We aimed at evaluating the role of 68 Ga-PSMA-11 PET/CT-derived metabolic parameters for assessment of whole-body tumor burden and its capability to determine therapeutic response in patients with prostate cancer. METHODS: A total of 142 patients with biochemical recurrence of prostate cancer underwent PET/CT with [68 Ga]Ga-PSMA-HBED-CC (68 Ga-PSMA-11). Quantitative assessment of all 641 68 Ga-PSMA-11-positive lesions in the field of view was performed to calculate PSMA-derived parameters, including whole-body PSMA tumor volume (PSMA-TV) and whole-body total lesion PSMA (TL-PSMA), as well as the established SUVmax and SUVmean values...
October 2018: European Journal of Nuclear Medicine and Molecular Imaging
https://read.qxmd.com/read/30929322/performance-and-impact-of-prostate-specific-membrane-antigen-based-diagnostics-in-the-management-of-men-with-biochemical-recurrence-of-prostate-cancer-and-its-role-in-salvage-lymph-node-dissection
#16
REVIEW
Marieke J Krimphove, Lena H Theissen, Alexander P Cole, Felix Preisser, Philipp C Mandel, Felix K H Chun
Up to 50% of patients initially treated for prostate cancer in a curative intent experience biochemical recurrence, possibly requiring adjuvant treatment. However, salvage treatment decisions, such as lymph node dissection or radiation therapy, are typically based on prostate specific antigen (PSA) recurrence. Importantly, common imaging modalities ( e.g. , computed tomography [CT], magnetic resonance imaging, and bone scan) are limited and the detection of recurrent disease is particularly challenging if PSA is low...
January 2020: World Journal of Men's Health
https://read.qxmd.com/read/31101746/predictors-of-overall-and-disease-free-survival-in-metastatic-castration-resistant-prostate-cancer-patients-receiving-225-ac-psma-617-radioligand-therapy
#17
JOURNAL ARTICLE
Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, Ismaheel O Lawal, Otto Knoesen, Johncy Mahapane, Cindy Davis, Florette Reyneke, Alex Maes, Clemens Kratochwil, Thabo Lengana, Frederik L Giesel, Christophe Van de Wiele, Alfred Morgenstern
Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA), making this antigen a suitable target for radioligand therapy of the disease. Here we report on our experience with a series of 73 castration-resistant prostate carcinoma patients treated with 225 Ac-PSMA-617, identifying variables predictive for overall survival (OS) and progression-free survival (PFS) after 225 Ac-PSMA-617 treatment. Methods: 225 Ac-PSMA-617 was administered to patients who had metastatic castration-resistant prostate carcinoma and who had exhausted available therapy options for their disease...
January 2020: Journal of Nuclear Medicine
https://read.qxmd.com/read/31021918/comparison-of-recist-irecist-and-percist-for-the-evaluation-of-response-to-pd-1-pd-l1-blockade-therapy-in-patients-with-non-small-cell-lung-cancer
#18
COMPARATIVE STUDY
Lucian Beer, Maximilian Hochmair, Alexander R Haug, Bernhard Schwabel, Daria Kifjak, Wolfgang Wadsak, Thorsten Fuereder, Hannah Fabikan, Andreas Fazekas, Sophia Schwab, Marius E Mayerhoefer, Christian Herold, Helmut Prosch
PURPOSE: The aim of this study was to compare the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the immune RECIST (iRECIST) criteria, and the Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) 1.0 in patients with advanced non-small cell lung cancer treated with programmed cell death protein 1 (PD-1)/programmed cell death protein 1 ligand (PD-L1) inhibitors. METHODS: This prospective study of 42 patients treated with a PD-1/PD-L1 inhibitor was approved by our institutional review board, and all patients gave written, informed consent...
July 2019: Clinical Nuclear Medicine
https://read.qxmd.com/read/30929846/a-systematic-review-on-the-role-of-imaging-in-early-recurrent-prostate-cancer
#19
JOURNAL ARTICLE
Pieter J L De Visschere, Chloë Standaert, Jurgen J Fütterer, Geert M Villeirs, Valeria Panebianco, Jochen Walz, Tobias Maurer, Boris A Hadaschik, Frédéric E Lecouvet, Gianluca Giannarini, Stefano Fanti
CONTEXT: In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA) level is a first sign of relapse, but imaging is needed to determine the localization of the recurrence, which may be local, in lymph nodes, and/or metastatic. With the increasing success rate of earlier salvage therapy, the diagnosis has become pertinent when the recurrent PSA level is still very low. OBJECTIVE: To systematically review the literature on the role of the existing imaging techniques in patients with early recurrent prostate cancer...
February 2019: European Urology Oncology
https://read.qxmd.com/read/31096849/radium-223-for-the-treatment-of-bone-metastases-in-castration-resistant-prostate-cancer-when-and-why
#20
REVIEW
Rosj Gallicchio, Pietro A Mastrangelo, Anna Nardelli, Pier Paolo Mainenti, Antonio P Colasurdo, Matteo Landriscina, Giuseppe Guglielmi, Giovanni Storto
Radium-223 dichloride (223 Ra) is the first, recently approved, α-particle-emitting radiopharmaceutical for the treatment of patients with bone metastases in castration-resistant prostate cancer (CRPC) and no evidence of visceral metastases. We explored MEDLINE, relevant congresses, and websites for data on 223 Ra and prostate cancer therapies, focusing on therapeutic strategies and timing, bone metastases, and diagnostic assessment. 223 Ra represents the only bone-targeting agent that has significantly extended patients' overall survival while reducing pain and symptomatic skeletal events...
October 2019: Tumori
label_collection
label_collection
4489
1
2
2019-06-07 22:46:54
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.